Business
Akebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial Officer
CAMBRIDGE, Mass., Jan. 9, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of
About this update from Akebia Therapeutics, Inc.
[{"type":"text","content":"CAMBRIDGE, Mass., Jan. 9, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of Nicholas Grund as Chief Commercial Officer. Mr. Grund is a seasoned pharmaceutical executive with significant operational, commercial and strategic leadership experience across renal and specialty markets.\n\n \n \n \n \n \n \n\n \n\"Nik is a profoundly knowledgeable executive with an impressive track record of leading commercial initiatives within the renal market,\" said John P. Butler, Chief Executive Officer of Akebia. \"His operational versatility and breadth of expertise in customer facing roles will be critical for Akebia as we prepare for the vadadustat launch in the U.S., if approved, and continue our goal to maximize Auryxia® (ferric citrate) revenue. We are pleased to welcome Nik to Akebia as he further strengthens our leadership team.\"\nPrior to joining Akebia, Mr. Grund served as President of Eurofins Transplant Genomics where he steered organizational change and facilitated continuous operating efficiency improvements and revenue growth. He was also Chief Commercial Officer of AMAG Pharmaceuticals where he managed commercial activities across four business units. Mr. Grund also held positions of increasing responsibility at Sanofi in its specialty care business and oversaw operations of its renal business unit.\n\"I am delighted to join the Akebia team at this pivotal moment,\" said Mr. Grund. \"Akebia has already built an impressive renal-focused commercial organization and their deep commitment to patients and connection to providers is evident. I am keen to build on the teams' efforts to prepare for the potential vadadustat launch with the ultimate goal of serving dialysis patients.\"\nAbout Akebia TherapeuticsAkebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.\nAbout VadadustatVadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to mimic the physiologic effect of altitude on o...